Cargando…

Observational Real-World Study to Assess Clinical Characteristics and Device Satisfaction in Patients with COPD Treated with Glycopyrrolate/eFlow(®) CS

PURPOSE: To assess clinical characteristics and device satisfaction of patients with chronic obstructive pulmonary disease (COPD) treated with glycopyrrolate/eFlow(®) Closed System (CS) nebulizer (further referred to as eFlow) under real-world conditions. PARTICIPANTS AND METHODS: Patients with COPD...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stephenson, Judith J, Dembek, Carole, Caldwell-Tarr, Amanda, Conto, Rebecca M, Paullin, Mark, Kerwin, Edward M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7369372/ https://www.ncbi.nlm.nih.gov/pubmed/32764916 http://dx.doi.org/10.2147/COPD.S248760

Ejemplares similares

In Vitro Characterization of the eFlow Closed System Nebulizer with Glycopyrrolate Inhalation Solution
por: Pham, Stephen, et al.
Publicado: (2018)

Glycopyrrolate/eFlow CS: The First Nebulized Long-Acting Muscarinic Antagonist Approved to Treat Chronic Obstructive Pulmonary Disease
por: Pleasants, Roy A.
Publicado: (2018)

In Vitro Effect of Different Airflow Rates on the Aerosol Properties of Nebulized Glycopyrrolate in the eFlow® Closed System and Tiotropium Delivered in the HandiHaler®
por: Ohar, Jill A., et al.
Publicado: (2020)

Dose selection for glycopyrrolate/eFlow(®) phase III clinical studies: results from GOLDEN (Glycopyrrolate for Obstructive Lung Disease via Electronic Nebulizer) phase II dose-finding studies
por: Donohue, James F., et al.
Publicado: (2017)

Clinically Important Deterioration Among Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Nebulized Glycopyrrolate: A Post Hoc Analysis of Pooled Data from Two Randomized, Double-Blind, Placebo-Controlled Studies
por: Kerwin, Edward M, et al.
Publicado: (2020)

Cost-effectiveness of twice-daily indacaterol/glycopyrrolate inhalation powder for the treatment of moderate to severe COPD in the US
por: Rajagopalan, Krithika, et al.
Publicado: (2018)

Efficacy of Nebulized Glycopyrrolate on Lung Hyperinflation in Patients with COPD
por: Siler, Thomas M., et al.
Publicado: (2021)

Bone and ocular safety of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a 52-week randomized study
por: Kerwin, Edward M., et al.
Publicado: (2019)

Lung function in adult patients with cystic fibrosis after using the eFlow(® )rapid for one year
por: Naehrig, S, et al.
Publicado: (2011)

Improved bioavailability of cromolyn sodium using inhaled PA101 delivered via eFlow® nebulizer
por: Abd-Elaziz, Khalid, et al.
Publicado: (2020)

Comparison of NUCLEOCOUNTER, ANDROVISION with Leja chambers and the newly developed ANDROVISION eFlow for sperm concentration analysis in boars
por: Grossfeld, Rudolf, et al.
Publicado: (2022)

Effect of background long-acting beta(2)-agonist therapy on the efficacy and safety of a novel, nebulized glycopyrrolate in subjects with moderate-to-very-severe COPD
por: Kerwin, Edward M, et al.
Publicado: (2018)

Impact of baseline clinical features on outcomes of nebulized glycopyrrolate therapy in COPD
por: Tashkin, Donald P., et al.
Publicado: (2021)

Efficacy and safety of four doses of glycopyrrolate/formoterol fumarate delivered via a metered dose inhaler compared with the monocomponents in patients with moderate-to-severe COPD
por: Reisner, Colin, et al.
Publicado: (2018)

Functional respiratory imaging assessment of budesonide/glycopyrrolate/formoterol fumarate and glycopyrrolate/formoterol fumarate metered dose inhalers in patients with COPD: the value of inhaled corticosteroids
por: van den Berge, Maarten, et al.
Publicado: (2021)

Extended Pharmacopeial Characterization of Surfactant Aerosols Generated by a Customized eFlow Neos Nebulizer Delivered through Neonatal Nasal Prongs
por: Bianco, Federico, et al.
Publicado: (2020)

Prospective Evaluation of Exacerbations Associated with Suboptimal Peak Inspiratory Flow Among Stable Outpatients with COPD
por: Mahler, Donald A, et al.
Publicado: (2022)

Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD
por: Fabbri, Leonardo M., et al.
Publicado: (2016)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Ohar, Jill A, et al.
Publicado: (2020)

Impact of Comorbidity Prevalence and Cardiovascular Disease Status on the Efficacy and Safety of Nebulized Glycopyrrolate in Patients with COPD
por: Putcha, Nirupama, et al.
Publicado: (2021)

Effect of SGRQ-Defined Chronic Bronchitis at Baseline on Treatment Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate
por: Tashkin, Donald P, et al.
Publicado: (2021)

Effect of Gender on Lung Function and Patient-Reported Outcomes in Patients with COPD Receiving Nebulized Glycopyrrolate [Corrigendum]
Publicado: (2021)

Efficacy of Glycopyrrolate in Primary Hyperhidrosis Patients
por: Lee, Hyun Ho, et al.
Publicado: (2012)

Glycopyrrolate in toxic exposure to ammonia gas
por: Bhalla, A, et al.
Publicado: (2011)

Glycopyrrolate-Induced Black Hairy Tongue
por: Prabha, Neel, et al.
Publicado: (2020)

Iontophoretic and Microneedle Mediated Transdermal Delivery of Glycopyrrolate
por: Gujjar, Meera, et al.
Publicado: (2014)

Glycopyrrolate-induced polyuria: An unexpected side effect
por: Behera, Sunil Kumar, et al.
Publicado: (2023)

Exacerbations and Real-World Outcomes After Single-Inhaler Triple Therapy of Budesonide/Glycopyrrolate/Formoterol Fumarate, Among Patients with COPD: Results from the EROS (US) Study
por: Strange, Charlie, et al.
Publicado: (2023)

Efficacy and safety of glycopyrrolate in patients with COPD by reversibility: pooled analysis of GEM1 and GEM2 12-week studies
por: Ohar, Jill A, et al.
Publicado: (2019)

24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD
por: Reisner, Colin, et al.
Publicado: (2017)

Characteristics of initiators of budesonide/glycopyrrolate/formoterol for treatment of chronic obstructive pulmonary disease (COPD) in the United States: the AURA study
por: Portillo, Edward C., et al.
Publicado: (2023)

New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology
por: D’Urzo, Anthony D, et al.
Publicado: (2018)

Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study
por: LaForce, Craig, et al.
Publicado: (2016)

Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS
por: Wang, Chen, et al.
Publicado: (2020)

Effectiveness of Oral Glycopyrrolate Use in Compensatory Hyperhidrosis Patients
por: Gong, Tai Kyung, et al.
Publicado: (2013)

Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease
por: Tashkin, Donald P, et al.
Publicado: (2018)

Impact of Sugammadex Versus Neostigmine/Glycopyrrolate on Perioperative Efficiency
por: Deyhim, Niaz, et al.
Publicado: (2020)

The Effect of Baseline Rescue Medication Use on Efficacy and Safety of Nebulized Glycopyrrolate Treatment in Patients with COPD from the GOLDEN 3 and 4 Studies
por: Donohue, James F, et al.
Publicado: (2020)

Role of nebulized glycopyrrolate in the treatment of chronic obstructive pulmonary disease
por: Santus, Pierachille, et al.
Publicado: (2017)

A case report: Glycopyrrolate for treatment of exercise-induced hyperhidrosis
por: Negaard, Matthew, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ahjpakr7f6juu7m18b1vst78fo